Trials / Terminated
TerminatedNCT00441558
A One-year Safety Study of Flibanserin to Treat Pre-Menopausal Women With Hypoactive Sexual Desire Disorder (HSDD).
Worldwide One-year Open-label Safety Study of Flibanserin in Women With HSDD
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 1,723 (actual)
- Sponsor
- Sprout Pharmaceuticals, Inc · Industry
- Sex
- Female
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Not accepted
Summary
To determine if long-term treatment with Flibanserin is safe and to monitor the effectiveness of Flibanserin in Women with HSDD that have already completed a previous study (511.70/71/.74/.75/.105) with Flibanserin.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Flibanserin | flexible dosing of either 50 or 100mg every evening, or 25 or 50mg twice daily. |
Timeline
- Start date
- 2007-02-01
- Primary completion
- 2009-08-01
- Completion
- 2009-08-01
- First posted
- 2007-03-01
- Last updated
- 2014-06-13
- Results posted
- 2014-06-13
Locations
196 sites across 2 countries: United States, Canada
Source: ClinicalTrials.gov record NCT00441558. Inclusion in this directory is not an endorsement.